1. Home
  2. ENTX vs KNDI Comparison

ENTX vs KNDI Comparison

Compare ENTX & KNDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Entera Bio Ltd.

ENTX

Entera Bio Ltd.

HOLD

Current Price

$2.93

Market Cap

147.4M

Sector

Health Care

ML Signal

HOLD

Logo Kandi Technologies Group Inc

KNDI

Kandi Technologies Group Inc

HOLD

Current Price

$0.61

Market Cap

61.9M

ML Signal

HOLD

Company Overview

Basic Information
Metric
ENTX
KNDI
Founded
2010
2002
Country
Israel
China
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Auto Manufacturing
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
147.4M
61.9M
IPO Year
2015
2021

Fundamental Metrics

Financial Performance
Metric
ENTX
KNDI
Price
$2.93
$0.61
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$9.00
N/A
AVG Volume (30 Days)
351.5K
69.8K
Earning Date
05-14-2026
04-28-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.22
N/A
Revenue
$42,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$13.68
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.91
$0.56
52 Week High
$4.20
$1.40

Technical Indicators

Market Signals
Indicator
ENTX
KNDI
Relative Strength Index (RSI) 50.89 38.27
Support Level $2.73 $0.57
Resistance Level $3.10 $0.70
Average True Range (ATR) 0.23 0.04
MACD -0.06 -0.00
Stochastic Oscillator 16.46 30.66

Price Performance

Historical Comparison
ENTX
KNDI

About ENTX Entera Bio Ltd.

Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.

About KNDI Kandi Technologies Group Inc

Kandi Technologies Group Inc is engaged in developing, manufacturing, and commercializing fully electric vehicle products and related technologies. Its products mainly consist of EV parts, EV products, and off-road vehicles, including All-Terrain Vehicles (ATVs), UTVs, go-karts, electric scooters, electric self-balancing scooters, and associated parts, and Lithium-ion cells, etc. The company generates maximum revenue from the sale of Off-road vehicles and associated parts. Geographically, it derives maximum revenue from the United States and other countries, followed by China.

Share on Social Networks: